Pharmaceuticals

TNF Pharmaceuticals

TNF Pharmaceuticals renamed to Q/C Technologies and launched new stock code

TNF Pharmaceuticals Secures Exclusive Rights to Cryptocurrency Light Computing Accelerator and Plans Private Placement Financing

TNF Pharmaceuticals released FY2025 Semi-Annual Earnings on August 19, 2025 (EST) with actual revenue of USD 0 and EPS of USD -44.6403

TNF Pharmaceuticals released FY2025 Q2 earnings on August 19 (EST) with actual revenue of USD 0 and EPS of USD -0.1766

TNF Pharmaceuticals Collaborates with DADA2 Foundation on Cynomel Compassionate Use Study

TNF Pharmaceuticals Annual Shareholders Meeting Approves Amendments to Common and Preferred Stock

TNF Pharmaceuticals released FY2025 Q1 earnings on May 15 (EST) with actual revenue of USD 0 and EPS of USD -36.2307

Positive GLP-1 Agonist Study Results, AI Aids Muscle Health

TNF Pharmaceuticals released FY2024 Q4 earnings on April 11, 2025 (EST), with actual revenue USD 0 and actual EPS USD -1.0906

TNF Pharmaceuticals released FY2024 Annual Earnings on April 11 (EST), with actual revenue of USD 0 and EPS of USD -1.115 K

TNF Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -1.079 K

TNF Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST) with actual revenue of 0 USD and EPS of -1.11 USD

TNF Pharmaceuticals Advances Leading Clinical Project for Age-Related Decline

TNF Pharmaceuticals released FY2024 Q2 earnings on August 19 (EST) with actual revenue of USD 0 and EPS of USD -454.4969

TNF Pharmaceuticals released FY2024 Semi-Annual earnings on August 19 (EST) with actual revenue of USD 0 and EPS of USD -9.5793

TNF Pharmaceuticals released FY2024 Q1 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -513.84

TNF Pharmaceuticals released FY2023 Q1 earnings on May 15, 2024 (EST) with actual revenue of USD 0 and EPS of USD -119.9586

TNF Pharmaceuticals released FY2022 Annual Earnings on April 1, 2024 (EST), Actual Revenue: USD 0, Actual EPS: USD -1.174 K

TNF Pharmaceuticals released FY2023 Q4 earnings on April 1 (EST), actual revenue USD 0, actual EPS USD -271.9337

TNF Pharmaceuticals released FY2023 Annual Earnings on April 1, 2024 (EST), Actual Revenue: USD 0, Actual EPS: USD -532.782

Davis Commodities

A SPAC III Acquisition

ECD Automotive Design

Can-Fite BioPharma

Sidus Space

PicoCELA

Northann

Highway

Aimei Health Tech

Pioneer Power

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap